COMMUNIQUÉS West-GlobeNewswire

Jasper Therapeutics Announces Briquilimab Development Program in Asthma
13/05/2024
Expanding Portfolio of Mast Cell Programs with Plans to Initiate a Phase 1b/2a study in Patients with Asthma in Q4 2024 Company to Host Key Opinion Leader Webinar on the Potential of Briquilimab in Asthma on May 20, [...]
Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference
13/05/2024
CUPERTINO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet [...]
GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
13/05/2024
Interim data readout of Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) expected Q3 2024 and topline data on track for Q4 2024 Ongoing progress of [...]
Verde Bio and SensaSure Technologies Complete Merger to Create Premier Mineral Acquisitions Company
13/05/2024
The combined company will focus on the acquisition and management of oil and gas of minerals and royalties Combined c ompany renamed Formation Minerals, Inc. and will be led by Mr. Scott Cox as President and Chief [...]
Recce Pharmaceuticals Reports Positive Preclinical Data of RECCE® 327 in Lung Infection Pilot Study
13/05/2024
RECCE ® 327 (R327) demonstrated >99% log reduction (>2.5 log reduction) in Mycobacterium abscessus lung infections using a nebulizer delivery method R327 is being evaluated for potential use to treat ventilator- [...]
IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update
13/05/2024
Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing DNA-mediated [...]
Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
13/05/2024
PHILADELPHIA, May 13, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed [...]
Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference
13/05/2024
WATERTOWN, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for [...]
Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
13/05/2024
CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced [...]
Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones
13/05/2024
Multiple Value-creating Catalysts Across the Annexon Portfolio Throughout 2024 Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected in Second Quarter 2024; Potential to be the First Targeted [...]
Collegium Announces $35 Million Accelerated Share Repurchase Program
13/05/2024
STOUGHTON, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious [...]
Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
13/05/2024
Topline single ascending dose (SAD) Phase 1 results of oral CDI-988, the first potential pan-coronavirus-pan-norovirus oral antiviral, expected in the second quarter of 2024 Enrollment completed in Phase 2a influenza A [...]
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
13/05/2024
OXFORD, United Kingdom, May 13, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide [...]
X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
13/05/2024
BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating [...]
Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA
13/05/2024
Petosemtamab granted BTD for the treatment of previously treated HNSCC UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company [...]
Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology
13/05/2024
Eight of nine experts expressed feeling “extremely confident” about prescribing ZORYVE foam to patients of diverse skin and hair types, including individuals with previous hair treatments, based on review of formulation [...]
ArcScan's Insight® 100 Ophthalmic Ultrasound Imaging System Approved in China
13/05/2024
First-of-its-Kind Computer-Controlled Robotic Instrument Receives NMPA Certification DENVER, May 13, 2024 (GLOBE NEWSWIRE) -- ArcScan, Inc., a global medical technology company dedicated to helping ophthalmologists [...]
Elutia to Showcase BioEnvelope Product Line at Heart Rhythm 2024
13/05/2024
SILVER SPRING, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, is excited to announce its participation in the upcoming Heart Rhythm [...]
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
13/05/2024
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update Landmark deal announced with Takeda for ACI-24.060 with $100 million upfront and total potential payments for option exercise and [...]

Pages